JPMorgan Starts Coverage on ChemoCentryx, Inc. (CCXI) at 'Overweight'; Shares Get Boost
Tweet
Share
E-mailGet Alerts CCXI Hot Sheet
Price: $14.07 --0%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Shares of ChemoCentryx, Inc. (Nasdaq: CCXI) are getting a boost from JPMorgan's initiation of coverage (at Overweight) this morning. The stock is up 2% heading into the close.
CCIX began trading back on Feb 8, 2012, getting as high as $12.77, before settling back down at $11. Since then, shares have been stuck between $10-11.70 with extrememly light volume.
ChemoCentryx, Inc. is a bio-pharmaceutical company that is focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
CCIX began trading back on Feb 8, 2012, getting as high as $12.77, before settling back down at $11. Since then, shares have been stuck between $10-11.70 with extrememly light volume.
ChemoCentryx, Inc. is a bio-pharmaceutical company that is focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Alibaba (BABA) PT Lowered to $160 at Baird
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
